Vaxxinity Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Vaxxinity.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

A Look At The Intrinsic Value Of Vaxxinity, Inc. (NASDAQ:VAXX)

Jan 08

Vaxxinity initiates rolling submission for its COVID-19 shot with UK's drug regulator

Sep 12

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vaxxinity has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:VAXX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	N/A	-57	-58	-57	N/A
9/30/2023	N/A	-66	-61	-60	N/A
6/30/2023	N/A	-72	-59	-58	N/A
3/31/2023	N/A	-75	-58	-56	N/A
12/31/2022	N/A	-75	-58	-56	N/A
9/30/2022	0	-103	-58	-55	N/A
6/30/2022	0	-114	-68	-65	N/A
3/31/2022	0	-123	-74	-72	N/A
12/31/2021	0	-137	-82	-81	N/A
9/30/2021	0	-102	-79	-78	N/A
6/30/2021	0	-88	-71	-71	N/A
3/31/2021	1	-68	-61	-60	N/A
12/31/2020	1	-40	-35	-34	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if VAXX's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if VAXX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if VAXX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if VAXX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if VAXX's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VAXX's Return on Equity is forecast to be high in 3 years time

Vaxxinity Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to US$13.50

Price target decreased to US$13.50

Recent updates

Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine

Vaxxinity Files Form 15

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

Vaxxinity, Inc. Receives A Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Vaxxinity, Inc. Announces the Publication of Data from Multiple Non-Human Primate Studies

Vaxxinity, Inc. to Present Data from UB-312 Program in Parkinson's Disease at International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog Disorders

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Vaxxinity, Inc. Announces Resignation of Katherine Eade from the Board of Directors

New major risk - Financial position

High number of new directors

Vaxxinity, Inc. Announces Executive Changes

Vaxxinity, Inc. Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer's Disease

New minor risk - Financial position

Vaxxinity, Inc. Announces Executive Changes

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease

Non-Employee Independent Director exercised options to buy US$1.0m worth of stock.

Less than half of directors are independent

Vaxxinity, Inc. Announces the Relocation of its Corporate Headquarters

A Look At The Intrinsic Value Of Vaxxinity, Inc. (NASDAQ:VAXX)

Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612

Price target decreased to US$13.50

Less than half of directors are independent

Price target decreased to US$13.50

Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine

Vaxxinity initiates rolling submission for its COVID-19 shot with UK's drug regulator

Vaxxinity's Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non Human Primates

Vaxxinity, Inc. Presents Preclinical Data on Tau Vaccine Candidates At the 2022 Alzheimer's Association International Conference

Less than half of directors are independent

The Coalition for Epidemic Preparedness Innovations to Co-Fund Vaxxinity, Inc.'s Pivotal Phase 3 UB-612 Heterologous Booster Trial to Combat SARS-CoV-2 variants

Less than half of directors are independent

Vaxxinity, Inc. Announces First Participant Dosed in Phase 3 Study of Next-Generation Covid-19 Vaccine Booster

Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern

Vaxxinity, Inc. Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Non-Employee Independent Director recently bought US$63k worth of stock

Co-Founder & Executive Chairman recently bought US$242k worth of stock

Less than half of directors are independent

Second quarter 2021 earnings released: US$0.39 loss per share

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies